



Published in final edited form as:

*Chem Commun (Camb)*. 2017 October 05; 53(80): 11012–11015. doi:10.1039/c7cc05403c.

## ***Helicobacter pylori* $\alpha$ 1–3/4-fucosyltransferase (Hp3/4FT)-catalyzed one-pot multienzyme (OPME) synthesis of Lewis antigens and human milk fucosides**

Hai Yu<sup>‡,a</sup>, Yanhong Li<sup>‡,a</sup>, Zhigang Wu<sup>‡,b</sup>, Lei Li<sup>b</sup>, Jie Zeng<sup>a,c</sup>, Chao Zhao<sup>a,d</sup>, Yijing Wu<sup>a,d</sup>, Nova Tasnima<sup>a</sup>, Jing Wang<sup>a,e</sup>, Huaide Liu<sup>a,f</sup>, Madhusudhan Reddy Gadi<sup>b</sup>, Wanyi Guan<sup>b,g</sup>, Peng G. Wang<sup>b</sup>, and Xi Chen<sup>a</sup>

<sup>a</sup>Department of Chemistry, University of California, One Shields Avenue, Davis, CA, 95616, USA. xiichen@ucdavis.edu; Tel: +1 530 754-6037; Fax: +1 530 752-8995

<sup>b</sup>Department of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA. pwang11@gsu.edu; Tel: +1 404 413-3591; Fax: +1 404 413-5505

<sup>c</sup>School of Food Science, Henan Institute of Science and Technology, Xinxiang, Henan 453003, China

<sup>d</sup>College of Food Science, Fujiang Agriculture and Forestry University, Fuzhou, Fujian 35002, China

<sup>e</sup>Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China

<sup>f</sup>School of Life Sciences, Nantong University, Seyuan Road 9, Nantong 226019, China

<sup>g</sup>College of Life Science, Hebei Normal University, Shijiazhuang, Hebei 050024, China

### **Abstract**


*Helicobacter pylori*  $\alpha$ 1–3/4-fucosyltransferase (Hp3/4FT) was expressed in *Escherichia coli* at a level of 30 mg/L culture and used as a diverse catalyst in a one-pot multienzyme (OPME) system for high-yield production of L-fucose-containing carbohydrates including Lewis antigens such as Lewis a, b, x, O-sulfated Lewis x, and sialyl Lewis x as well as human milk fucosides such as 3-fucosyllactose (3-FL), lacto-N-fucopentaose (LNFP) III, lacto-N-difuco-hexaose (LNDFH) II and III. Noticeably, while difucosylation of tetrasaccharides was readily achieved using an excess amount of donor, synthesis of LNFP III was achieved by Hp3/4FT-catalyzed selective fucosylation of the N-acetyllactosamine (LacNAc) component in lacto-N-neotetraose (LNnT).

### **Graphical abstract**

Lewis x, a, b, O-sulfated and sialyl Lewis x antigens, and fucosylated human milk oligosaccharides such as 3-FL, LNFP III, LNDFH II, and LNDFH III were efficiently produced using an Hp3/4FT-catalyzed one-pot multienzyme (OPME) fucosylation system.

Correspondence to: Peng G. Wang; Xi Chen.

<sup>‡</sup>These authors contributed equally.



Lewis antigens such as Lewis a ( $\text{Le}^a$ ),  $\text{Le}^b$ ,  $\text{Le}^x$ , and  $\text{Le}^y$  are Lfucose-containing glycans<sup>1</sup> presented abundantly on the surface of human red blood cells, endothelium and epithelium of various tissues such as kidney, genitourinary, and gastrointestinal tract.<sup>2,3</sup> Many of them are the binding targets for pathogenic bacteria that led to infection.<sup>1</sup>  $\text{Le}^a$  and  $\text{Le}^b$  are fucosylated type I chains containing a  $\text{Gal}\beta\text{3GlcNAc}$  disaccharide sequence and are mainly expressed in surface epithelia.<sup>4</sup> In comparison,  $\text{Le}^x$  and  $\text{Le}^y$  are fucosylated type II chains containing a  $\text{Gal}\beta\text{4GlcNAc}$  disaccharide sequence<sup>5</sup> and are expressed in deep glands.<sup>6</sup> The  $\alpha\text{1-3-}$  and  $\alpha\text{1-4-}$ linked Lfucoses are essential structure components of  $\text{Le}^x/\text{Le}^y$  and  $\text{Le}^a/\text{Le}^b$  antigens, respectively.

$\alpha\text{1-3/4-}$ Linked fucosides are also abundant in human milk oligosaccharides (HMOS)<sup>7</sup> where they have been found to have prebiotic, anti-adhesive antimicrobial, and immunomodulating activities which contribute significantly to the benefits of breast feeding.<sup>8-12</sup> In general,  $\alpha\text{1-3-}$ fucosylated HMOS were found to be protective for human immunodeficiency virus (HIV)-exposed uninfected children during breastfeeding.<sup>13</sup> Lewis antigen-type HMOS were shown to reduce selectin-mediated cell-cell interactions.<sup>14, 15</sup>

Fucosylated glycans have received great attention due to their potential applications as nutraceuticals and pharmaceuticals. Various synthetic methods have been explored. Compared to chemical fucosylation approaches which require tedious hydroxyl group protection and deprotection, efficient and environmentally friendly enzymatic fucosylation via fucosyltransferase-catalyzed reactions is a preferred route.

Among reported  $\alpha\text{1-3-}$ ,  $\alpha\text{1-4-}$ , and  $\alpha\text{1-3/4-}$ fucosyltransferases,<sup>16-26</sup> *Helicobacter pylori* UA948  $\alpha\text{1-3/4-}$ fucosyltransferase (Hp3/4FT) that can use both type I and type II glycans as acceptors<sup>22, 25</sup> draw our attention as an attractive catalyst. Nevertheless, its application in synthesizing fucosylated glycans has not been fully explored. Here, we report the use of Hp3/4FT in a highly efficient one-pot three-enzyme (OP3E) fucosylation system for the synthesis of diverse  $\alpha\text{1-3-}$  and  $\alpha\text{1-4-}$ linked fucosides, including  $\text{Le}^a$ ,  $\text{Le}^b$ ,  $\text{Le}^x$ , *O*-sulfated  $\text{Le}^x$ , sialyl  $\text{Le}^x$ , and human milk fucosides 3-FL, LNFP III, LNDFH II and III.

To obtain an active C-His<sub>6</sub>-tagged Hp3/4FT, the gene of C-terminal 34 amino acid-truncated Hp3/4FT from *H. pylori* strain UA948 (GenBank Accession number AAF35291.2, full length 462 aa) was codon optimized and cloned into pET22b(+) vector. Expression in *E. coli* BL21(DE3) cells led to about 30 mg of soluble protein that could be routinely purified from 1 liter culture using a  $\text{Ni}^{2+}$ -column (Figure S1, ESI<sup>†</sup>). As other bacterial  $\alpha\text{1-3-}$ ,  $\alpha\text{1-4-}$ , and

<sup>†</sup>Electronic Supplementary Information (ESI) available: Experimental details for enzyme characterization and glycan synthesis, NMR and HRMS data, and NMR spectra.

$\alpha$ 1–3-/4-fucosyltransferases, Hp3/4FT belongs to glycosyltransferase family 10 (GT10) in the Carbohydrate Active Enzyme (CAZy) database ([www.cazy.org](http://www.cazy.org)).<sup>27, 28</sup> It shares more than 78% sequence identity with other FTs from *H. pylori* (Figure S2, ESI<sup>†</sup>).

Using fluorophore 2-anthranilic acid (2AA)-labeled disaccharides (Lac $\beta$ Pro2AA, LacNAc $\beta$ Pro2AA, and Gal $\beta$ 3GlcNAc $\beta$ Pro2AA) as acceptor substrates in high-performance liquid chromatography (HPLC) assays, pH profiles (Figure S3, ESI<sup>†</sup>) showed similar patterns although optimal activity of Hp3/4FT was observed in a broader pH range when LacNAc $\beta$ 2AA was used as the acceptor (6.0–9.0) compared to that (pH 7.0–9.0) for Lac $\beta$ Pro2AA and Gal $\beta$ 3GlcNAc $\beta$ Pro2AA. In addition, Hp3/4FT was more efficient in using LacNAc $\beta$ Pro2AA and Gal $\beta$ 3GlcNAc $\beta$ Pro2AA as acceptors and a lower amount of enzyme (0.24  $\mu$ g) was used in the assays compared to Lac $\beta$ Pro2AA (1.9  $\mu$ g enzyme). The fucosyltransferase activity decreased dramatically when the pH was below 6.0 or above 9.0 (for Lac $\beta$ 2AA and Gal $\beta$ 3GlcNAc $\beta$ Pro2AA) or 10.0 (for LacNAc $\beta$ Pro2AA). The thermal stability assays of Hp3/4FT indicated that the enzyme was stable at 30 °C or lower for at least 60 min. The enzyme activity decreased dramatically by incubation at 37 °C and an almost complete loss of activity was observed at 40 °C (Figure S4, ESI<sup>†</sup>). At 4 °C, Hp3/4FT was stable for at least two months without activity decrease.

A metal ion was not required for the fucosyltransferase activity of Hp3/4FT as 10 mM of EDTA did not alter its activity significantly (Figure S5, ESI<sup>†</sup>). Nevertheless, the presence of 10 mM of divalent metal ions such as Ca<sup>2+</sup>, Co<sup>2+</sup>, Mg<sup>2+</sup>, Mn<sup>2+</sup>, or Ni<sup>2+</sup> increased the enzyme activity slightly while the presence of Cu<sup>2+</sup> decreased the activity about three-fold. Although Hp3/4FT has three cysteine residues, the presence of 10 mM dithiothreitol (DTT) did not affect the activity of the enzyme.

As shown in Table 1 (kinetic plots in Figure S6, ESI<sup>†</sup>), among three 2AA-labelled acceptor substrates, Hp3/4FT showed the highest catalytic efficiency for LacNAc $\beta$ 2AA ( $k_{cat}/K_M = 10.87 \text{ s}^{-1} \text{ mM}^{-1}$ ) due to the lowest  $K_M$  value ( $0.46 \pm 0.07 \text{ mM}$ ) and a medium range  $k_{cat}$  ( $5.00 \pm 0.18 \text{ s}^{-1}$ ). Gal $\beta$ 3GlcNAc $\beta$ 2AA had a medium catalytic efficiency ( $5.89 \text{ s}^{-1} \text{ mM}^{-1}$ ) with the worst  $K_M$  ( $1.32 \pm 0.24 \text{ mM}$ ) and the highest  $k_{cat}$  ( $7.77 \pm 0.45 \text{ s}^{-1}$ ). Lac $\beta$ 2AA had the lowest catalytic efficiency ( $k_{cat}/K_M = 0.55 \text{ s}^{-1} \text{ mM}^{-1}$ ) with a medium  $K_M$  value ( $k_{cat}/K_M = 0.99 \pm 0.18 \text{ mM}$ ) and the lowest  $k_{cat}$  value ( $0.54 \pm 0.03 \text{ s}^{-1}$ , more than 9-fold lower than the other two). Hp3/4FT also showed different catalytic efficiencies ( $0.80 \text{ s}^{-1} \text{ mM}^{-1}$ ,  $7.01 \text{ s}^{-1} \text{ mM}^{-1}$ , and  $11.19 \text{ s}^{-1} \text{ mM}^{-1}$ ) for guanosine 5'-diphosphate fucose (GDP-Fuc) when different acceptors (Lac $\beta$ 2AA, LacNAc $\beta$ 2AA, and Gal $\beta$ 1–3GlcNAc $\beta$ 2AA) were used.

With no noticeable fucosidase activity observed when tested using Le<sup>x</sup> $\beta$ ProN<sub>3</sub>, Le<sup>x</sup> $\beta$ pNP, or Le<sup>a</sup> $\beta$ ProN<sub>3</sub> as a substrate, Hp3/4FT was readily applied in a one-pot three-enzyme (OP3E) fucosylation system for the synthesis of various  $\alpha$ 1–3- and/or  $\alpha$ 1–4-linked fucosides (Scheme 1). In this system, GDP-Fuc was formed from L-fucose, adenine 5'-triphosphate (ATP), and guanosine 5'-triphosphate (GTP) using a bifunctional *Bacteroides fragilis* enzyme (BfFKP) with both L-fucokinase and GDP-Fuc pyrophosphorylase activities.<sup>29</sup> *Pasteurella multocida* inorganic pyrophosphatase (PmPpA)<sup>30</sup> was used to break down the pyrophosphate byproduct to drive the formation of GDP-Fuc which was used as the donor substrate for Hp3/4FT for the formation of fucosides.

As shown in Table 2, all disaccharides (**1–6**), and tetrasaccharides (**7–9**) tested were well suited acceptor substrates for Hp3/4FT for the production of mono- or difucosylated products (**11–19**). These included type I disaccharide Gal $\beta$ 3GlcNAc $\beta$ OR (**1**)<sup>31</sup> and its analog Gal $\beta$ 3GlcNAc $\alpha$ OR (**2**)<sup>31</sup> where R was a propyl azide (ProN<sub>3</sub> aglycon). They were  $\alpha$ 1–4-fucosylated by Hp3/4FT to produce mono-fucosylated products Gal $\beta$ 3(Fuca4)GlcNAc $\beta$ ProN<sub>3</sub> (**11**, Le<sup>a</sup> antigen) and Gal $\beta$ 3(Fuca4)GlcNAc $\alpha$ ProN<sub>3</sub> (**12**) in excellent 95% and 96% yields, respectively. Type II disaccharide Gal $\beta$ 4GlcNAc $\beta$ OR (**3**)<sup>30</sup> and its 6-*O*-sulfated analog Gal $\beta$ 4GlcNAc6S $\beta$ OR (**4**)<sup>32</sup> were also excellent acceptors for  $\alpha$ 1–3-fucosylation by Hp3/4FT to produce Gal $\beta$ 4(Fuca3)GlcNAc $\beta$ ProN<sub>3</sub> (**13**, Le<sup>x</sup> antigen) and Gal $\beta$ 4(Fuca3)GlcNAc6S $\beta$ ProN<sub>3</sub> (**14**) in 98% and 93% yields, respectively. Mono-fucosylation of Type VI disaccharide Gal $\beta$ 4Glc $\beta$ OR (**5**)<sup>33–35</sup> and lactose (**6**) led to the formation of Gal $\beta$ 4(Fuca3)Glc $\beta$ ProN<sub>3</sub> (**15**) and 3-fucosyllactose [**16**, 3-FL, Gal $\beta$ 4(Fuca3)Glc] in 92% and 90% yields, respectively. 3-FL is one of the most abundant fucosylated HMOS that could inhibit bacterial or viral adhesion to human epithelial cells.<sup>36</sup>

Both Gal $\beta$ 3/4GlcNAc and Gal $\beta$ 4Glc components in lacto-*N*-tetraose (**7**, LNT, Gal $\beta$ 3GlcNAc $\beta$ 3Gal $\beta$ 4Glc) and lacto-*N*-neotetraoside (**9**, LNnT $\beta$ ProN<sub>3</sub>, Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ ProN<sub>3</sub>)<sup>37, 38</sup> are suitable fucosylation sites for Hp3/4FT. Fucosylation with an excess amount of Lfucose, ATP, and GTP (3 equivalents each) led to the formation of difucosylated hexasaccharides Gal $\beta$ 3(Fuca4)GlcNAc $\beta$ 3Gal $\beta$ 4(Fuca3)Glc (**17**) and Gal $\beta$ 4(Fuca3)GlcNAc $\beta$ 3Gal $\beta$ 4(Fuca3)Glc $\beta$ ProN<sub>3</sub> (**19**) in excellent 98% and 99% yields, respectively. Compound **17** (lacto-*N*-difuco-hexaose II, or LNDFH II)<sup>39</sup> is a hexasaccharide containing both  $\alpha$ 1–3- and  $\alpha$ 1–4-linked fucose and is presented in human milk at a level of 0.08–0.1 g L<sup>-1</sup>.<sup>40</sup> While compound **19** is the glycoside of another human milk hexasaccharide lacto-*N*-neodifucohexaose II (LNnDFH II or LNDFH III).<sup>12</sup> Quite remarkably, if the ratio of GDP-Fuc to lacto-*N*-neotetraose (**8**, LNnT) was set to 1.2:1, Hp3/4FT selectively catalyzed the transfer of fucose to the LacNAc (instead of lactose) component in LNnT and led to the formation of LNFP III (**18**) as characterized by MALDI-TOF tandem mass spectrometry and 2D nuclear magnetic resonance (NMR) spectroscopy (Figure S7, ESI<sup>†</sup>). This acceptor site preference was consistent with the kinetics study results.

Sialylated type II glycan Neu5Ac $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ OR was also a good acceptor for  $\beta$ 1–3-fucosylation by Hp3/4FT to produce Neu5Ac $\alpha$ 3Gal $\beta$ 4(Fuca3)GlcNAc $\beta$ ProN<sub>3</sub> (**20**, sialyl Le<sup>x</sup> antigen) in 84% yield. In comparison, Neu5Ac $\alpha$ 3Gal $\beta$ 4Glc $\beta$ OR and sialyl type I glycan Neu5Ac $\alpha$ 3Gal $\beta$ 3GlcNAc $\beta$ OR were poor acceptors for Hp3/4FT.

The Hp3/4FT was also used for the synthesis of a Le<sup>b</sup> antigen which has both  $\alpha$ 1–2- and  $\alpha$ 1–4-linked fucose residues (Scheme 2). The  $\alpha$ 1–2-fucose was installed to type I disaccharide Gal $\beta$ 3GlcNAc $\beta$ ProN<sub>3</sub> (**1**) to produce H type I trisaccharide<sup>22</sup> Fuca2Gal $\beta$ 3GlcNAc $\beta$ ProN<sub>3</sub> (**21**) by a one-pot three-enzyme fucosylation system containing BfFKP, PmPpA, and a highly efficient  $\alpha$ 1–2-fucosyltransferase cloned from *Thermosynechococcus elongatus* (Te2FT).<sup>41</sup> Le<sup>b</sup> tetrasaccharide Fuca2Gal $\beta$ 3(Fuca4)GlcNAc $\beta$ ProN<sub>3</sub> (**22**) was successfully obtained in 98% yield, indicating  $\alpha$ 1–2-fucosylation of type I glycan did not affect its recognition by Hp3/4FT as an acceptor. However, attempts to alter the fucosylation sequence by performing Te2FT-

catalyzed  $\alpha$ 1–2-fucosylation of Le<sup>a</sup> (**11**) was not successful, indicating that  $\alpha$ 1–3-fucosylation of type I glycan blocked Te2FT activity. The result was similar to that reported previously.<sup>22</sup>

In conclusion, the recombinant Hp3/4FT was readily expressed in *E. coli* and purified with a high expression level (30 mg/L culture). It was used as an efficient catalyst in an OP3E fucosylation system for synthesizing various  $\alpha$ 1–3- and/or  $\alpha$ 1–4-linked mono- and difucosylated compounds including Lewis x, a, and b antigens, sialyl Le<sup>x</sup>, and fucosylated human milk oligosaccharides such as 3-FL, LNFP III, LNDFH II, and LNDFH III. These fucosides are important probes for biological studies.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This work was supported by National Institutes of Health (NIH) Common Fund grants U01GM120419 and U01GM0116263 as well as NIH grant R01HD065122. Bruker Avance-800 NMR spectrometer was funded by National Science Foundation grant DBIO-722538. Y.L., H.Y., and X.C. are co-founders of Glycohub, Inc., a company focused on the development of carbohydrate-based reagents, diagnostics, and therapeutics. Glycohub, Inc. played no role in the design, execution, interpretation, or publication of this study.

## References

1. Becker DJ, Lowe JB. *Glycobiology*. 2003; 13:41R–53R.
2. Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Ruvoen N, Clement M, Le Pendu J. *Biochimie*. 2001; 83:565–573. [PubMed: 11522384]
3. Holgersson J, Breimer ME, Samuelsson BE. *APMIS Supplementum*. 1992; 27:18–27. [PubMed: 1520526]
4. Inagaki H, Sakamoto J, Nakazato H, Bishop AE, Yura J. *J Surg Oncol*. 1990; 44:208–213. [PubMed: 2385097]
5. Green C. *FEMS Microbiol Immunol*. 1989; 1:321–330. [PubMed: 2698728]
6. Kobayashi K, Sakamoto J, Kito T, Yamamura Y, Koshikawa T, Fujita M, Watanabe T, Nakazato H. *Am J Gastroenterol*. 1993; 88:919–924. [PubMed: 8503388]
7. Wu S, Tao N, German JB, Grimm R, Lebrilla CB. *J Proteome Res*. 2010; 9:4138–4151. [PubMed: 20578730]
8. Newburg DS, Ruiz-Palacios GM, Morrow AL. *Annu Rev Nutr*. 2005; 25:37–58. [PubMed: 16011458]
9. Fei Y, Sun YS, Li Y, Yu H, Lau K, Landry JP, Luo Z, Baumgarth N, Chen X, Zhu X. *Biomolecules*. 2015; 5:1480–1498. [PubMed: 26193329]
10. Kunz C, Rudloff S, Baier W, Klein N, Strobel S. *Annu Rev Nutr*. 2000; 20:699–722. [PubMed: 10940350]
11. Smilowitz JT, Lebrilla CB, Mills DA, German JB, Freeman SL. *Annu Rev Nutr*. 2014; 34:143–169. [PubMed: 24850388]
12. Chen X. *Adv Carbohydr Chem Biochem*. 2015; 72:113–190. [PubMed: 26613816]
13. Kuhn L, Kim HY, Hsiao L, Nissan C, Kankasa C, Mwiya M, Thea DM, Aldrovandi GM, Bode L. *J Nutr*. 2015; 145:66–72. [PubMed: 25527660]
14. Bode L, Kunz C, Muhly-Reinholz M, Mayer K, Seeger W, Rudloff S. *Thromb Haemost*. 2004; 92:1402–1410. [PubMed: 15583750]
15. Bode L, Rudloff S, Kunz C, Strobel S, Klein N. *J Leukoc Biol*. 2004; 76:820–826. [PubMed: 15240751]

16. Dumon C, Samain E, Priem B. *Biotechnol Prog.* 2004; 20:412–419. [PubMed: 15058985]
17. Choi YH, Kim JH, Park BS, Kim BG. *Biotechnol Bioeng.* 2016; 113:1666–1675. [PubMed: 26804479]
18. Baisch G, Ohrlein R, Streiff M, Kolbinger F. *Bioorg Med Chem Lett.* 1998; 8:755–758. [PubMed: 9871536]
19. Martin SL, Edbrooke MR, Hodgman TC, van den Eijnden DH, Bird MI. *J Biol Chem.* 1997; 272:21349–21356. [PubMed: 9261148]
20. Sugiarto G, Lau K, Yu H, Vuong S, Thon V, Li Y, Huang S, Chen X. *Glycobiology.* 2011; 21:387–396. [PubMed: 20978012]
21. Lin SW, Yuan TM, Li JR, Lin CH. *Biochemistry.* 2006; 45:8108–8116. [PubMed: 16800635]
22. Rasko DA, Wang G, Palcic MM, Taylor DE. *J Biol Chem.* 2000; 275:4988–4994. [PubMed: 10671538]
23. Leonard R, Lhernould S, Carlue M, Fleurat P, Maftah A, Costa G. *Glycoconj J.* 2005; 22:71–78. [PubMed: 15864437]
24. Rabbani S, Miksa V, Wipf B, Ernst B. *Glycobiology.* 2005; 15:1076–1083. [PubMed: 16000696]
25. Ma B, Audette GF, Lin S, Palcic MM, Hazes B, Taylor DE. *J Biol Chem.* 2006; 281:6385–6394. [PubMed: 16407247]
26. Lee JH, Pandey RP, Kim D, Sohng JK. *Biotechnol Bioproc E.* 2013; 18:843–849.
27. Campbell JA, Davies GJ, Bulone V, Henrissat B. *Biochem J.* 1997; 326(Pt 3):929–939. [PubMed: 9334165]
28. Coutinho PM, Deleury E, Davies GJ, Henrissat B. *J Mol Biol.* 2003; 328:307–317. [PubMed: 12691742]
29. Yi W, Liu X, Li Y, Li J, Xia C, Zhou G, Zhang W, Zhao W, Chen X, Wang PG. *Proc Natl Acad Sci U S A.* 2009; 106:4207–4212. [PubMed: 19251666]
30. Lau K, Thon V, Yu H, Ding L, Chen Y, Muthana MM, Wong D, Huang R, Chen X. *Chem Commun.* 2010; 46:6066–6068.
31. Yu H, Thon V, Lau K, Cai L, Chen Y, Mu S, Li Y, Wang PG, Chen X. *Chem Commun.* 2010; 46:7507–7509.
32. Santra A, Yu H, Tasnima N, Muthana MM, Li Y, Zeng J, Kenyon NJ, Louie AY, Chen X. *Chem Sci.* 2016; 7:2827–2831. [PubMed: 28138383]
33. de Mattos LC. *Rev Bras Hematol Hemoter.* 2016; 38:331–340. [PubMed: 27863762]
34. Ye J, Liu X, Peng P, Yi W, Chen X, Wang F, Cao H. *ACS Catal.* 2016; 6:8140–8144.
35. Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X. *J Am Chem Soc.* 2005; 127:17618–17619. [PubMed: 16351087]
36. Montreuil J. *C R Hebd Seances Acad Sci.* 1956; 242:192–193.
37. McArthur JB, Yu H, Zeng J, Chen X. *Org Biomol Chem.* 2017; 15:1700–1709. [PubMed: 28134951]
38. Yu H, Zeng J, Li Y, Thon V, Shi B, Chen X. *Org Biomol Chem.* 2016; 14:8586–8597. [PubMed: 27548611]
39. Kuhn R, Gauhe A. *Chem Ber-Recl.* 1960; 93:647–651.
40. Chaturvedi P, Warren CD, Altaye M, Morrow AL, Ruiz-Palacios G, Pickering LK, Newburg DS. *Glycobiology.* 2001; 11:365–372. [PubMed: 11425797]
41. Zhao C, Wu Y, Yu H, Shah IM, Li Y, Zeng J, Liu B, Mills DA, Chen X. *Chem Commun.* 2016; 52:3899–3902.





Scheme 2.

Enzymatic synthesis of Le<sup>b</sup> antigen (**22**) by Hp3/4FT-catalyzed OP3E fucosylation of H type I trisaccharide (**1**) formed by Te2FT-catalyzed OP3E fucosylation reaction.



**Table 1**  
**Apparent kinetic parameters of Hp3/4FT**





















Substrate	$k_{\text{cat}}$ (s <sup>-1</sup> )	$K_{\text{M}}$ (mM)	$k_{\text{cat}}/K_{\text{M}}$ (s <sup>-1</sup> mM <sup>-1</sup> )
Lac $\beta$ Pro2AA	0.54±0.03	0.99±0.18	0.55
<sup>a</sup> GDP-Fuc	0.30±0.14	0.38±0.07	0.80
LacNAc $\beta$ Pro2AA	5.00±0.18	0.46±0.07	10.87
<sup>b</sup> GDP-Fuc	6.02±0.26	0.86±0.13	7.01
Gal $\beta$ 3GlcNAc $\beta$ Pro2AA	7.77±0.45	1.32±0.24	5.89
<sup>c</sup> GDP-Fuc	3.92±0.16	0.35±0.06	11.19

<sup>a</sup>Determined using Lac $\beta$ Pro2AA as an acceptor

<sup>b</sup>Determined using LacNAc $\beta$ Pro2AA as an acceptor

<sup>c</sup>Determined using Gal $\beta$ 3GlcNAc $\beta$ Pro2AA as an acceptor.

**Table 2**  
**One-pot three-enzyme (OP3E) synthesis of  $\alpha$ .1–3/4-linked fucosides**

Entry	Acceptor	Product	Yield (%)
a	 1	 11	95
b	 2	 12	96
c	 3	 13	98
d	 4	 14	93
e	 5	 15	92
f	 6	 16	90
g	 7	 17	98
h	 8	 18	88
i	 9	 19	99
j	 10	 20	84